COMPASS PATHWAYS PLC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
COMPASS PATHWAYS PLC (CMPS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $138.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-24
- COMPASS PATHWAYS PLC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $138.00K, a 99.04% decline from fiscal 2024.
- COMPASS PATHWAYS PLC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $14.38M, a 34.10% increase from fiscal 2023.
- COMPASS PATHWAYS PLC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $10.72M, a 97.68% increase from fiscal 2022.
- COMPASS PATHWAYS PLC effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $5.42M, a 44.73% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $138.00K 10-K · filed 2026-03-24 |
| 2024-12-31 | $14.38M 10-K · filed 2026-03-24 |
| 2023-12-31 | $10.72M 10-K · filed 2025-02-27 |
| 2022-12-31 | $5.42M 10-K · filed 2024-02-29 |
| 2021-12-31 | $3.75M 10-K · filed 2024-02-29 |
| 2020-12-31 | $1.66M 10-K · filed 2023-02-28 |
| 2019-12-31 | $1.04M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |